Abstract
Giant cell tumour of bone (GCT) is an aggressive primary neoplasm that results in the production of osteolytic lesions. Stromal cells, which form the main neoplastic component of this tumor, regulate the formation of osleoclast-like giant cells that are ultimately responsible for bone destruction. Bisphosphonates prevent bone resorption by inhibiting osteoclast activity and promoting osteoclast apoptosis, and they have been known to induce apoptosis of primary neoplastic cells such as those in breast and prostate cancers. We hypothesized that in bisphosphonates may induce apoptosis not only in osteoclast-like giant cells but also in neoplastic stromal cells of GCT both in vitro and in vivo. Twelve patients with GCT were treated with weekly injections of pamidronate for a period of 6 weeks prior to surgery. GCT specimens were collected at the time of biopsy and during definitive surgery. TUNEL assay was used to evaluate apoptotic DNA fragmentation in cells. In addition, twelve GCT primary cultures from these patients were treated with zoledronate, pamidronate, or alendronate for 48 hours at different doses (3, 30, or 150 μM) and subjected to apoptosis assay by flow cytometry following fluorescent Annexin-V labeling. The results showed that pamidronate significantly induced apoptosis in both osteoclast-like giant cells and stromal tumor cells, in vivo. All three bisphosphonates caused substantial apoptosis of stromal tumor cells in cultures. Zoledronate was the most potent reagent, resulting in an average cell death of 27.41% at 150 μM, followed by pamidronate (22.23%) and alendronate (15.3%). Our observations suggest that these drugs may be considered as potential adjuvants in the treatment of GCT.
Similar content being viewed by others
References
RE Turcotte FH Sim KK Unni (1993) ArticleTitleGiant cell tumour of the sacrum. Clin Orthop 291 215–221 Occurrence Handle8504603
MH Zheng P Robbins J Xu L Huang DJ Wood JM Papadimitriou (2001) ArticleTitleThe histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 16 297–307 Occurrence Handle1:STN:280:DC%2BD3M7ks1Crsg%3D%3D Occurrence Handle11193206
M Wuelling C Engels N Jesse M Werner E Kaiser G Delling (2002) ArticleTitleHistogenesis of giant cell tumors. Pathologe 23 332–339 Occurrence Handle10.1007/s00292-002-0552-2 Occurrence Handle1:STN:280:DC%2BD38nnvFaqsg%3D%3D Occurrence Handle12376858
Y Abe K Yonemura K Nishida K Takagi (1994) ArticleTitleGiant cell tumor of bone: analysis of proliferative cells by double-labeling immunohistochemistry with anti-proliferating cell nuclear antigen antibody and culture procedure. Nippon Seikeigeka Gakkai Zasshi 68 407–414 Occurrence Handle1:STN:280:ByuA38fgtFc%3D Occurrence Handle7914219
D Robinson TA Einhorn (1994) ArticleTitleGiant cell tumour of bone: a unique paradigm of stroma-hematopoietic cellular interactions. J Cell Biochem 55 330–303
MA Ghert M Rizzo JM Harrelson SP Scully (2002) ArticleTitleGiant-cell tumor of the appendicular skeleton. Clin Orthop 400 201–210 Occurrence Handle12072763
F Masui (1998) ArticleTitleGiant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int 48 723–729 Occurrence Handle1:STN:280:DyaK1cvkvFGlsg%3D%3D Occurrence Handle9778111
MG Rock (1990) ArticleTitleCurettage of giant cell tumor of bone. Factors influencing local recurrences and metastasis. Chir Organi Mov 75 IssueID(suppl 1 43–46
S Boutou-Bredaki P Agapios G Papachristou (2001) ArticleTitlePrognosis of giant cell tumor of bone. Histopathological analysis of 15 cases and review of the literature. Adv Clin Path 5 IssueID3 71–78 Occurrence Handle1:STN:280:DC%2BD38%2FgtFahtw%3D%3D Occurrence Handle11753878
PM Bonecamp (1986) ArticleTitleTwo modes of action of bisphosphonate on osteoclastic resorption of mineralized matrix. J Bone Miner Res 1 27–39
AM Flanagan TJ Chambers (1991) ArticleTitleInhibition of bone resorption by bisphosphonate:interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49 407–415 Occurrence Handle1:CAS:528:DyaK38Xht1Srt7k%3D Occurrence Handle1840176
GA Rodan (1998) ArticleTitleMechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 38 375–388 Occurrence Handle10.1146/annurev.pharmtox.38.1.375 Occurrence Handle1:CAS:528:DyaK1cXivF2iurk%3D Occurrence Handle9597160
MJ Rogers DJ Watts RG Russell (1997) ArticleTitleOverview of bisphosphonates. Cancer (Phila) 80 1652–1660 Occurrence Handle10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z Occurrence Handle1:CAS:528:DyaK2sXmvFyht7s%3D
CW Lowik G Pluijm Particlevan der LJ Wee-Pals Particlevan der HB Treslong-De Groot Particlevan OL Bijvoet (1988) ArticleTitleMigration and phenotypic transformation of osteoclast precursors into mature osteoclast the effect of bisphosphonate. J Bone Miner Res 3 85–192
DE Hughes KR Wright HL Uy (1995) ArticleTitleBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 1478–1487 Occurrence Handle1:CAS:528:DyaK2MXpsFGmsbo%3D Occurrence Handle8686503
KS Selander J Mönkkönen Karhukorpi EK P Härkönen R Hannuniemi HK Väänänen (1996) ArticleTitleCharacteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50 1127–1138 Occurrence Handle1:CAS:528:DyaK28XntFCqsrk%3D Occurrence Handle8913344
SP Luckman DE Hughes FP Coxon R Graham G Russell MJ Rogers (1998) ArticleTitleNitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 581–589 Occurrence Handle1:CAS:528:DyaK1cXisFyktb8%3D Occurrence Handle9556058
FP Coxon HL Benford RG Russell MJ Rogers (1998) ArticleTitleProtein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol. Pharmacol 54 631–638 Occurrence Handle1:CAS:528:DyaK1cXmvVWjt7s%3D Occurrence Handle9765505
CM Shipman PI Croucher RGG Russell MJ Rogers (1998) ArticleTitleThe bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58 5294–5297 Occurrence Handle1:CAS:528:DyaK1cXotVSktr8%3D Occurrence Handle9850051
SS Virtanen HK Vaananen PL Harkonen PT Lakkakorpi (2002) ArticleTitleAlendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 62 2708–2714 Occurrence Handle1:CAS:528:DC%2BD38XjtlGrtLw%3D Occurrence Handle11980672
S Jurgen E Vera T Borna B Joachim W Winfried V Frans van (2001) ArticleTitleThe bisphosphoate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12 459 Occurrence Handle10.1097/00001813-200106000-00007 Occurrence Handle11395574
P Clezardin J Gligorov P Delmas (2000) ArticleTitleMechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine 67 IssueID1 22 Occurrence Handle1:STN:280:DC%2BD3c3jsFOrsg%3D%3D Occurrence Handle10773965
AW Yasko (2002) ArticleTitleGiant cell tumor of bone. Curr Oncol Rep 4 520–526 Occurrence Handle12354366
YY Cheng L Huang KM Lee FM Lai JSK Tam SM Kumta (2003) ArticleTitleCytochemical and ultrastructural study of the osteoclast-like giant cells of GCT following bisphosphonate administration. Ultrastruct Pathol 27 385–391 Occurrence Handle14660277
Acknowledgments
This study was supported by grants from the Chinese University of Hong Kong (Ref No. 2040918 and 2003.1.065) to Prof. S. M. Kumta. We are grateful to Dr. K. Li at Department of Paediatrics, the Chinese University of Hong Kong, for her guidance of the flow cytometry analysis. Alendronate was, as aforementioned, a kind gift from Merck Sharp and Dohme (Ireland) Ltd.
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors (Y.Y. Cheng and L. Huang) contributed equally to this work.
Rights and permissions
About this article
Cite this article
Cheng, Y.Y., Huang, L., Lee, K.M. et al. Bisphosphonates Induce Apoptosis of Stromal Tumor Cells in Giant Cell Tumor of Bone. Calcif Tissue Int 75, 71–77 (2004). https://doi.org/10.1007/s00223-004-0120-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-004-0120-2